Updates

Loungers

January 2021

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

In a period marred by trading restrictions, Loungers delivered +25.1% like-for-like sales growth (materially beating the sector) between re-opening in mid-July and 4th October. EBITDA margins were +660bps as it flexed its costs and harnessed all available government support and that led to EBITDA only falling 9% to £13.2m with pretax profit being £0.1m (H1 ’19: loss £2.5m) in the six months to 4th October. Cash generation jumped from £12.5m to almost £21m and net debt fell by £21.9m to £13.6m, helped by the £8.1m equity raise and VAT deferral.As at 2nd December, 60 of its 168 sites are still closed (in Tier 3) after the end of Lockdown 2.0. An order at table app (used for 70% sa ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

UDG Healthcare - Operating margin at Sharp jumps from 12.9% to 15.5%

Ibstock

Loungers - Agreed bid at 310p; gain 172% (January 2025)

Loungers (December 2024)

Loungers - Opening 35 casual dining outlets annually there’s plenty of runway to 665 target (September 2024)

Loungers (June 2024)

Loungers - Strong trading delivers new upgrade (January 2024)

Loungers - Like-for-like sales accelerate to almost 10% (December 2023)

Loungers - Roll-out target upped from 400 to 600 (September 2023)

Loungers (June 2023)

Loungers (February 2023)

Loungers - Accelerating new openings from 24 to 32 as it eyes 500 outlets (September 2022)

Loungers (June 2022)

Loungers (February 2022)

Loungers (December 2020)

Loungers (October 2020)

Loungers - Best-in-class cafe bar group looks set to beat forecasts (September 2020)

Loungers - New issue moves to healthy premium (June 2019)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X